{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:51:59Z","timestamp":1777553519977,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.vaccine.2023.03.012","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T15:32:10Z","timestamp":1682782330000},"page":"3467-3471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Immunogenicity and immune persistence in 4-year-old children completing four doses of Sabin strain or wild strain inactivated poliovirus vaccine: A phase IV, open-labeled, parallel-controlled observational study"],"prefix":"10.1016","volume":"41","author":[{"given":"Kai","family":"Chu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongmei","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weining","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.03.012_b0005","unstructured":"WHO, Poliomyelitis. https:\/\/www.who.int\/zh\/news-room\/fact-sheets\/detail\/poliomyelitis [Accessed Aug 31, 2022]."},{"key":"10.1016\/j.vaccine.2023.03.012_b0010","unstructured":"WHO, Two out of three wild poliovirus strains eradicated. 24 October 2019. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/two-out-of-three-wild-poliovirus-strains-eradicated [Accessed Aug 31, 2022]."},{"key":"10.1016\/j.vaccine.2023.03.012_b0015","unstructured":"WHO, Poliomyelitis (polio). https:\/\/www.who.int\/health-topics\/poliomyelitis#tab=tab_1 [Accessed Aug 31, 2022]."},{"key":"10.1016\/j.vaccine.2023.03.012_b0020","unstructured":"Global Polio Eradication Initiative, Polio this week as of 24 August. https:\/\/polioeradication.org\/polio-today\/polio-now\/this-week\/ [Accessed Aug 31, 2022]."},{"key":"#cr-split#-10.1016\/j.vaccine.2023.03.012_b0025.1","unstructured":"Polio vaccines: WHO position paper - June 2022. Weekly Epidemiological Record. vol. 97, 25"},{"key":"#cr-split#-10.1016\/j.vaccine.2023.03.012_b0025.2","unstructured":"2022. https:\/\/www.who.int\/publications\/i\/item\/WHO-WER9725-277-300 [Accessed Aug 31, 2022]."},{"key":"10.1016\/j.vaccine.2023.03.012_b0030","unstructured":"Global Polio Eradication Initiative, Polio Eradication Strategy 2022\u223c2026. https:\/\/apps.who.int \u203a handle \u203a 9789240026025 [Accessed Aug 31, 2022]."},{"key":"10.1016\/j.vaccine.2023.03.012_b0035","unstructured":"Chinese Center for Disease Control and Prevention, China adjusts immunization program for polio vaccine and measles-containing vaccine. http:\/\/www.nhc.gov.cn\/jkj\/s3590\/202001\/f1b793e053ea49d3b4251fe107ada325.shtml [Accessed Aug 31, 2022]."},{"issue":"45","key":"10.1016\/j.vaccine.2023.03.012_b0040","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1016\/j.vaccine.2018.09.023","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, dose-finding trial[J]","volume":"36","author":"Chu","year":"2018","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2023.03.012_b0045","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/infdis\/jiy736","article-title":"Immunogenicity and safety of a Sabin strain\u2013based inactivated polio vaccine: a phase 3 clinical trial[J]","volume":"220","author":"Hu","year":"2019","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2023.03.012_b0050","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14760584.2021.1919091","article-title":"Cross-neutralization capacity of immune serum from different dosage of Sabin inactivated poliovirus vaccine immunization against multiple individual polioviruses[J]","volume":"20","author":"Chu","year":"2021","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2023.03.012_b0055","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.vaccine.2008.10.061","article-title":"Need for polio boosters after age two years[J]","volume":"27","author":"Rennels","year":"2008","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2023.03.012_b0060","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/jpids\/piv017","article-title":"Immunogenicity of two different sequential schedules of inactivated polio vaccine followed by oral polio vaccine versus oral polio vaccine alone in healthy infants in China[J]","volume":"5","author":"Li","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"36","key":"10.1016\/j.vaccine.2023.03.012_b0065","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1016\/j.vaccine.2014.08.091","article-title":"Immunogenicity and persistence from different 3-dose schedules of live and inactivated polio vaccines in Chinese infants[J]","volume":"33","author":"Lu","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.03.012_b0070","unstructured":"World Health Organization. Polio laboratory manual, 4th ed. World Health Organization; 2004. https:\/\/apps.who.int\/iris\/handle\/10665\/68762 [Accessed Aug 31, 2022]."},{"key":"10.1016\/j.vaccine.2023.03.012_b0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.trivac.2015.08.001","article-title":"Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies[J]","volume":"4","author":"Resik","year":"2015","journal-title":"Trials Vaccinol"},{"key":"10.1016\/j.vaccine.2023.03.012_b0080","unstructured":"WHO, Vaccination schedule for Cuba. https:\/\/immunizationdata.who.int\/pages\/schedule-by-country\/cub.html?DISEASECODE=&TARGETPOP_GENERAL= [Accessed Aug 31, 2022]."},{"issue":"42","key":"10.1016\/j.vaccine.2023.03.012_b0085","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/j.vaccine.2014.07.109","article-title":"Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba[J]","volume":"32","author":"Resik","year":"2014","journal-title":"Vaccine"},{"issue":"11\u201312","key":"10.1016\/j.vaccine.2023.03.012_b0090","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.vaccine.2003.10.026","volume":"22","author":"Langue","year":"2004","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2023.03.012_b0095","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4161\/hv.7.5.14982","article-title":"Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS\u00ae) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio\u00ae) given as a booster dose at 6 years of age [J]","volume":"7","author":"Gajdos","year":"2011","journal-title":"Hum Vaccin"},{"issue":"32","key":"10.1016\/j.vaccine.2023.03.012_b0100","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1016\/j.vaccine.2015.06.036","article-title":"Diphtheria, tetanus and poliovirus antibody persistence 5 years after vaccination of pre-schoolers with two different diphtheria, tetanus and inactivated poliomyelitis vaccines (Td-IPV or DT-IPV) and immune responses to a booster dose of DTaP-IPV[J]","volume":"33","author":"Gajdos","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2023.03.012_b0105","first-page":"212","article-title":"Evaluation of immune persistence of vaccine[J]","volume":"56","author":"Chen","year":"2022","journal-title":"Zhonghua yu Fang yi xue za zhi [Chin J Prevent Med]"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23002591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23002591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:27:19Z","timestamp":1759404439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23002591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":22,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0264410X23002591"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.012","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and immune persistence in 4-year-old children completing four doses of Sabin strain or wild strain inactivated poliovirus vaccine: A phase IV, open-labeled, parallel-controlled observational study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}